ClinicalTrials.gov
public full text
Public Domain
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the ODISSEA Study.#833294
- Non clinic-Based Interventions to Mitigate Post-Intensive Care Syndrome: A Scoping Review.#288584
- CDC Prevention Epicenters Wake Up and Breathe Collaborative#858951
- Optimal Timing for Spontaneous Breathing Trials#907369
- A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults#858520
Record · ID 846320
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive